Summer of M&A: what's happened in the nutra world and what it means for the industry

The VMS land grab

Big supplement M&A dominated the headlines. Procter & Gamble kicked things off in August with its $3.8bn purchase of Thorne from L Catterton, seeing off reported interest from Unilever. The purchase signalled that mainstream consumer goods players now see clinically validated, practitioner-trusted VMS brands as a genuine growth category rather than a side bet.

Days later, Japan's Kirin Holdings agreed to a $1.36bn deal for Jamieson Wellness, folding the Canadian heritage brand into a health science portfolio that already includes Blackmores and FANCL.

Then came the flip side of the same coin: the middle of the VMS market is being sorted into "premium and clinical" versus "scale and distribution," with each camp buying differently. For example, Nestlé's $1bn sale of seven VMS brands (including Nature's Bounty, Nuun and Osteo Bi-Flex) to private equity firm Yellow Wood Partners is a case in point. Rather than a retreat from wellness, this was a sharpening of focus: Nestlé opted to keep Solgar and Pure Encapsulations, its premium, science-led names, and offload its mainstream mass-market business to an owner built for that model. Bain Capital's earlier move on Vitabiotics also fitted the same pattern.

Beverages go functional

Nestlé also announced a $5.6bn joint venture with Platinum Equity, spinning off more than 30 water and premium beverage brands — including S.Pellegrino and Perrier — into a new standalone business: Peranel. It's not a nutraceutical deal in the traditional sense, but it confirms that hydration and functional beverages are being treated as a distinct growth platform, with its own R&D team and acquisition mandate.

Expect Peranel to be an active buyer in functional hydration during the next 12-18 months.

Ingredients consolidate around the GLP-1 effect

The ingredients side of the business saw the most consequential deal of the summer: Ingredion's £2.7bn acquisition of Tate & Lyle created a combined $9.9bn ingredient solutions group built around fibre, protein and sugar-reduction. This is squarely aimed at formulators adapting products for GLP-1 users who are eating less but demanding more nutritional density per serving.